Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation
| Image |  |
|---|---|
| Description | scientific article published on 18 April 2019 |
| Author/s |
author: Koen van Besien Mike Wei Giorgio Inghirami Elizabeth Margolskee Steven M Horwitz Alexandra Gomez-Arteaga |
| Publication date | April 18, 2019 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |